An interventional study of TENS in Vagus Nerve Stimulation, Acute Coronary Syndrome and Ischemia Reperfusion Injury, sponsored by Bakulev Scientific Center of Cardiovascular Surgery. Completed at 1 site in Russia. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Bakulev Scientific Center of Cardiovascular Surgery · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
At the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains the leading one. However, despite the high efficiency of providing medical care to patients with acute coronary syndrome (ACS), there remains a high mortality and disability of this group of patients. In this regard, the search for new drug and non-drug strategies for the treatment of patients with ACS is actively continuing. Over the past decade, it has been shown that transcutaneous vagus nerve stimulation (TENS) has a cardioprotective effect both in chronic heart failure and in coronary heart disease, improves cardiac function, prevents reperfusion injury, weakens myocardial remodeling, increases the effectiveness of defibrillation and reduces the size of a heart attack. One of the methods of noninvasive stimulation of the afferent fibers of the vagus nerve is percutaneous electrical stimulation of the auricular branch of the vagus nerve. However, further studies are needed to determine whether stimulation of the tragus can improve the long-term clinical outcome in this cohort of patients.
ACS is a combined concept for such life-threatening conditions as acute myocardial infarction (AMI) and unstable angina, which are exacerbations of coronary heart disease. However, despite the high effectiveness of the invasive treatment strategy, there remains a high mortality and disability of this group of patients. One of the reasons for this problem is reperfusion injury of the myocardium during revascularization, since reperfusion itself causes myocardial damage, known as Myocardial Ischemia Reperfusion Injury (MIRI). Every year, new data from experimental studies and small clinical trials appear, confirming the concept that MIRI makes a big contribution to the final size of a heart attack and cardiac myocardial function. Currently, there is no specific treatment aimed at MIRI in patients with STEMI. Thus, new treatment methods are needed that can reduce MIRI in revascularized patients. In the course of small clinical studies, it was shown that against the background of vagus nerve stimulation, a significant decrease in heart rate occurs, inflammatory processes and cellular apoptosis are suppressed, left ventricular remodeling decreases and myocardial contractile function improves. Also, a significant decrease in MIRI is demonstrated with percutaneous stimulation of the vagus nerve in the acute period of myocardial infarction. The data of the first clinical trial with VNS in patients with STEMI were published in 2017 (doi:10.1016/j.jcin.2017.04.036). This experimental study increases the likelihood that this noninvasive therapy can be used to treat patients with STEMI who are undergoing primary percutaneous coronary intervention (PCI). New studies are needed to prove the safety and effectiveness of vagus nerve stimulation in patients with STEMI.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
This study's enrollment of 110 is below the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →Bakulev Scientific Center of Cardiovascular Surgery is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
It will be performed attached to the tragus of the left ear.
Device: TENS
It will be performed attached to the earlobe of the left ear.
Device: TENS
TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
Hospital mortality
The number of patients who died in the hospital.
Time frame: From date of randomization until the date of death from any cause, assessed up to 14 days.
30-day mortality
The number of patients who died within 30 days from the development of myocardial infarction.
Time frame: From date of randomization until the date of death from any cause, assessed up to 30 days.
Number of participants with non-lethal events.
The main hospital non-lethal events (Pulmonary edema, Cardiogenic shock, Cardiac arrhythmias: Atrial fibrillation, Ventricular tachycardia/fibrillation, Accelerated idioventricular rhythm/Atrioventricular block II, III).
Time frame: From the date of randomization to the date of any of the listed events, assessed up to 14 days.
Assessment of the level of myocardial damage.
Dynamics of Troponin I (hs-cTnI) in blood plasma.
Time frame: Diagnosis will be carried out during hospitalization, after 6 hours and on the 4th day of hospitalization.
Assessment of the level of inflammation.
Dynamics of high-sensitivity C-reactive protein (hs-CRP) in blood plasma. Dynamics of copeptin (CPP) in blood plasma.
Time frame: Diagnosis will be carried out during hospitalization and after 24 hours.
Assessment of the level of heart failure
Dynamics of NT-proBNP in blood plasma.
Time frame: Diagnosis will be carried out during hospitalization and on the 4th day of hospitalization.
Plan to share: No
Ran from Sep 2022 to primary completion in Mar 2026, 42 months.
Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's 42 months is above that.
Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bakulev Scientific Center of Cardiovascular Surgery